Some Biomarkers in Bronchial Asthma in Children

NCT ID: NCT04175093

Last Updated: 2019-11-25

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 105 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-11-29
• Study Completion Date: 2021-11-21

Brief Summary

Asthma, a disease characterized by chronic airway inflammation and hyper -responsiveness, is a common disease that affects all age groups. Asthma may be manifested as irreversible airflow obstruction in some patients. Although the pathogenesis of asthma is not well understood, increased oxidative stress due to an imbalance of oxidants and antioxidants has been found to be associated with asthma. In asthma, inflammation-related oxidative stress is driven by exposure to a variety of triggers, including allergens and viruses, which activate components of both the innate and acquired immune responses. Protection by escaping from triggering factors or standardization of asthma medication is difficult and usually is not enough for effective treatment. On the other hand, correction of antioxidative systems may be more efficacious in the control of asthmatic inflammation and asthma symptoms.

Little is known about the role of asymmetric dimethylarginine in the pathogenesis of asthmatic airway inflammation. The lung is a major source of asymmetric dimethylarginine that can promote oxidative stress by a reduction in nitric oxide synthesis which would result in higher levels of peroxynitrite, that causes oxidative cell damage, and exacerbate airway inflammation. asymmetric dimethylarginine can modify lung function, increase airway hyper-reactivity even in non-inflamed airways, and promote lung collagen production and deposition. Increased asymmetric dimethylarginine in serum has been found to be associated with the severity of symptoms of asthma in obese adults.

Malondialdehyde is an oxidant marker of pulmonary oxidative stress, and lipid peroxidation. Paraoxonase, an antioxidant enzyme may play a protective role in asthma. It hydrolyzes lipid peroxides and prevents low-density lipoprotein oxidation.

Conditions

Bronchial Asthma

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Mild persistent asthma

• Group I, patients with mild persistent asthma.

asymmetric dimethylarginine

Intervention Type: DIAGNOSTIC_TEST

measurement by ELISA of asymmetric dimethylarginine

Moderate persistent asthma

• Group II, patients with moderate persistent asthma.

asymmetric dimethylarginine

Intervention Type: DIAGNOSTIC_TEST

measurement by ELISA of asymmetric dimethylarginine

Severe persistent asthma

• Group III ,patients with severe persistent asthma.

asymmetric dimethylarginine

Intervention Type: DIAGNOSTIC_TEST

measurement by ELISA of asymmetric dimethylarginine

Interventions

asymmetric dimethylarginine

measurement by ELISA of asymmetric dimethylarginine

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Exclusion Criteria

• Obese children,
• The presence of chronic heart, liver and kidney diseases, concomitant chronic inflammatory disease and autoimmune disorders, and Diabetes mellitus.
• Patients taking antioxidant drugs, vitamins, diuretics, hormone replacement therapy will be also excluded.
• Children aged less than six years. 5-children who have symptoms of lower or upper respiratory tract infection or asthma exacerbation within the previous four weeks.

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Sara Safwat Abd-Elaleem Hafez

Principal investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

BRASTHMA

Identifier Type: -

Identifier Source: org_study_id